CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.